



Biologic & Otezla Switching in Psoriatic Arthritis

OVERVIEW

The psoriatic arthritis market is being ignited by the recent introductions of new biologics and novel oral treatments, with the pipeline promising even more innovation. Over the coming months and years, the conventional treatment paradigm of DMARDs and TNF-alpha inhibitors will be seriously challenged. As more biologics and novel small molecule agents are introduced into the market, second and third line positioning becomes increasingly important.

RealWorld Dynamix: Biologic and Otezla Switching in Psoriatic Arthritis analyzes the dynamics associated with switching between biologic brands and Otezla. This robust patient audit covers the progression from PsA diagnosis to first biologic initiation to most recent switch, understanding what clinical and non-clinical factors drive switching and what role the patient plays. In addition, forward looking content reveals the looming threats to each brand and highlights areas of lost opportunity at the switch point.

SAMPLE & METHODOLOGY

RealWorld Dynamix: Psoriatic Arthritis is based on a retrospective analysis of ~1,000 patient records for PsA patients who have recently been switched from one biologic brand or Otezla to a different brand. In addition to patient demographics and treatment history, clinical assessments, diagnostic tests and laboratory values are included to provide insight into the clinical course of the disease. An understanding of why the patient was discontinued from the prior brand and what features of the new brand led to its selection give insight into the competitive positioning. The audits are completed by ~200 qualifying rheumatologists.

KEY QUESTIONS ANSWERED

- What is the co-management relationship of the PsA patient with dermatologists and which party is making initial and subsequent decisions about biologic/Otezla treatment?
- When and why do physicians switch treatments?
- Which co-morbidities are associated with each brand and how often are these co-morbidities a factor in switching?
- At what point do rheumatologists move to an alternate mechanism agent?
- Is Otezla being used before TNF agents? In which patients?

Products Profiled:

Commercial Products*:

AbbVie (Humira), Amgen/Pfizer (Enbrel), Celgene (Otezla), Janssen (Remicade, Simponi, Stelara), UCB Pharma (Cimzia)

Pipeline Agents:

AstraZeneca/Valeant (brodalumab), Lilly (ixekizumab), BMS (Orencia), Novartis (Cosentyx), Pfizer (Xeljanz)

**Brand names and trademarks of respective organizations*

Key Dates:

Published December 2015

Deliverables:

- PowerPoint report
- Frequency Tables & Summary Statistics Transcriptions of qualitative interviews
- On-site presentation

Related Reports:

RealTime Dynamix: Psoriatic Arthritis (US)

RealTime Dynamix: Rheumatoid Arthritis (US)

RealWorld Dynamix: Rheumatoid Arthritis (US)